154 related articles for article (PubMed ID: 2225234)
1. Schedule dependence of buthionine sulfoximine in reversing resistance to cisplatin.
Robichaud NJ; Fram RJ
Chem Biol Interact; 1990; 76(3):333-42. PubMed ID: 2225234
[TBL] [Abstract][Full Text] [Related]
2. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.
Mistry P; Loh SY; Kelland LR; Harrap KR
Int J Cancer; 1993 Nov; 55(5):848-56. PubMed ID: 8244583
[TBL] [Abstract][Full Text] [Related]
3. Intracellular glutathione levels in human colon cancer cells naturally resistant to cross-linking agents.
Ozawa S; Iwata K; Kubodera A; Inaba M
J Pharmacobiodyn; 1989 Jul; 12(7):378-83. PubMed ID: 2593079
[TBL] [Abstract][Full Text] [Related]
4. The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line.
Meijer C; Mulder NH; Hospers GA; Uges DR; de Vries EG
Br J Cancer; 1990 Jul; 62(1):72-7. PubMed ID: 2390486
[TBL] [Abstract][Full Text] [Related]
5. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links.
Chen G; Zeller WJ
Anticancer Res; 1991; 11(6):2231-7. PubMed ID: 1776864
[TBL] [Abstract][Full Text] [Related]
6. Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion.
Andrews PA; Schiefer MA; Murphy MP; Howell SB
Chem Biol Interact; 1988; 65(1):51-8. PubMed ID: 3345573
[TBL] [Abstract][Full Text] [Related]
7. In vitro investigations on induction and reversal of cisplatin resistance in a rat ovarian tumor cell line.
Chen G; Zeller WJ
J Cancer Res Clin Oncol; 1990; 116(5):443-7. PubMed ID: 2121738
[TBL] [Abstract][Full Text] [Related]
8. [Potentiation of cisplatin sensitivity of cisplatin-resistant human ovarian cancer cell lines by L-buthionine-S,R-sulfoximine].
Kudoh K; Kita T; Hirata J; Ishii K; Hiramatsu H; Kikuchi Y; Nagata I
Nihon Sanka Fujinka Gakkai Zasshi; 1994 Jun; 46(6):525-32. PubMed ID: 8040625
[TBL] [Abstract][Full Text] [Related]
9. Circumvention of drug resistance in cisplatin-resistant sublines of the human squamous carcinoma cell line HLac 79 in vitro and in vivo.
Bier H
Acta Otolaryngol; 1991; 111(4):797-806. PubMed ID: 1950544
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of antitumor activity of cisplatin on human gastric cancer cells in vitro and in vivo by buthionine sulfoximine.
Saikawa Y; Kubota T; Kuo TH; Furukawa T; Tanino H; Watanabe M; Ishibiki K; Kitajima M
Jpn J Cancer Res; 1993 Jul; 84(7):787-93. PubMed ID: 8370654
[TBL] [Abstract][Full Text] [Related]
11. Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells.
Ali-Osman F; Antoun G; Wang H; Rajagopal S; Gagucas E
Mol Pharmacol; 1996 Jun; 49(6):1012-20. PubMed ID: 8649339
[TBL] [Abstract][Full Text] [Related]
12. Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines.
Lai GM; Ozols RF; Young RC; Hamilton TC
J Natl Cancer Inst; 1989 Apr; 81(7):535-9. PubMed ID: 2493524
[TBL] [Abstract][Full Text] [Related]
13. Effect of D,L-buthionine-S,R-sulfoximine on cytotoxicity and DNA cross-linking induced by bifunctional DNA-reactive cytostatic drugs in human melanoma cells.
Hansson J; Edgren M; Ehrsson H; Ringborg U; Nilsson B
Cancer Res; 1988 Jan; 48(1):19-26. PubMed ID: 3334994
[TBL] [Abstract][Full Text] [Related]
14. Sensitive enzymatic cycling assay for glutathione: measurements of glutathione content and its modulation by buthionine sulfoximine in vivo and in vitro in human colon cancer.
Berger SJ; Gosky D; Zborowska E; Willson JK; Berger NA
Cancer Res; 1994 Aug; 54(15):4077-83. PubMed ID: 8033140
[TBL] [Abstract][Full Text] [Related]
15. [Increasing chemosensitivity to cisplatin by glutathione depletion with buthionine sulfoximine. In vitro and in vivo studies with a human squamous cell cancer line].
Bier H
Laryngorhinootologie; 1990 Jan; 69(1):16-20. PubMed ID: 2310456
[TBL] [Abstract][Full Text] [Related]
16. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
Lai SL; Hwang J; Perng RP; Whang-Peng J
Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042
[TBL] [Abstract][Full Text] [Related]
17. Exogenous glutathione attenuates the antiproliferative effect of buthionine sulfoximine.
Kang YJ
Toxicology; 1994 Mar; 88(1-3):177-89. PubMed ID: 8160199
[TBL] [Abstract][Full Text] [Related]
18. Nitrogen mustard-DNA interaction in melphalan-resistant mammary carcinoma cells with elevated intracellular glutathione and glutathione-S-transferase activity.
Alaoui-Jamali MA; Panasci L; Centurioni GM; Schecter R; Lehnert S; Batist G
Cancer Chemother Pharmacol; 1992; 30(5):341-7. PubMed ID: 1505071
[TBL] [Abstract][Full Text] [Related]
19. Buthionine sulfoximine enhances glutathione-but attenuates glutamate-stimulated cell proliferation.
Kang YJ
Cell Mol Biol Res; 1995; 41(2):131-6. PubMed ID: 8581064
[TBL] [Abstract][Full Text] [Related]
20. Effects of buthionine sulfoximine treatment on cellular glutathione levels and cytotoxicities of cisplatin, carboplatin and radiation in human stomach and ovarian cancer cell lines.
Lee KS; Kim HK; Moon HS; Hong YS; Kang JH; Kim DJ; Park JG
Korean J Intern Med; 1992 Jul; 7(2):111-7. PubMed ID: 1306072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
